These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17070267)

  • 1. Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study.
    Lazzeri M; Calò G; Spinelli M; Malaguti S; Guerrini R; Salvadori S; Beneforti P; Regoli D; Turini D
    J Urol; 2006 Nov; 176(5):2098-102. PubMed ID: 17070267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study.
    Lazzeri M; Calò G; Spinelli M; Guerrini R; Salvadori S; Beneforti P; Sandri S; Regoli D; Turini D
    Urology; 2003 May; 61(5):946-50. PubMed ID: 12736013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study.
    Lazzeri M; Calò G; Spinelli M; Guerrini R; Beneforti P; Sandri S; Zanollo A; Regoli D; Turini D
    J Urol; 2001 Dec; 166(6):2237-40. PubMed ID: 11696742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
    Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
    J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
    Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
    J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.
    Giannantoni A; Di Stasi SM; Stephen RL; Bini V; Costantini E; Porena M
    J Urol; 2004 Jul; 172(1):240-3. PubMed ID: 15201783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
    Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
    Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
    Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial.
    Silva C; Silva J; Ribeiro MJ; Avelino A; Cruz F
    Eur Urol; 2005 Oct; 48(4):650-5. PubMed ID: 15961217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical vanilloids and neurogenic incontinence: ten years experience.
    Lazzeri M; Spinelli M; Zanollo A; Turini D
    Urol Int; 2004; 72(2):145-9. PubMed ID: 14963356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gabapentin treatment of neurogenic overactive bladder.
    Carbone A; Palleschi G; Conte A; Bova G; Iacovelli E; Bettolo CM; Pastore A; Inghilleri M
    Clin Neuropharmacol; 2006; 29(4):206-14. PubMed ID: 16855422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2).
    Kennelly M; Cruz F; Herschorn S; Abrams P; Onem K; Solomonov VK; Del Rosario Figueroa Coz E; Manu-Marin A; Giannantoni A; Thompson C; Vilain C; Volteau M; Denys P;
    Eur Urol; 2022 Aug; 82(2):223-232. PubMed ID: 35400537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Marque P; Rischmann P; Gamé X
    World J Urol; 2016 May; 34(5):755-61. PubMed ID: 26282099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
    Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
    Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder.
    Kaga K; Yamanishi T; Kaga M; Fuse M; Kamasako T; Ishizuka M
    Int J Urol; 2020 Oct; 27(10):899-904. PubMed ID: 32767525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study.
    de Sèze M; Gallien P; Denys P; Labat JJ; Serment G; Grise P; Salle JY; Blazejewski S; Hazane C; Moore N; Joseph PA
    Neurourol Urodyn; 2006; 25(7):752-7. PubMed ID: 16986136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.